SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (460)2/3/2009 11:31:01 AM
From: rkrw  Read Replies (1) | Respond to of 508
 
Funny I had thought about the exact same thing. Antidepressants and antihistamines. Given some recent deal structures, I think there's no question they can partner if they choose to particularly if they're flexible with the upfront which only seems fair given the mixed outcome.



To: Biomaven who wrote (460)2/3/2009 8:02:14 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 508
 
If you look at most approved antidepressants, you'll see they mostly did something like 4 or more trials to get 2 that showed significance. So speaking cynically, worst case they partner this and run a couple more trials to end up with an approved $1b product in a few years.

I don’t especially like your analogy. Depression has a much stronger placebo effect than IPF.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News